BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15853443)

  • 1. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
    Glimelius B
    Drug Saf; 2005; 28(5):417-33. PubMed ID: 15853443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
    Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    Kuehr T; Ruff P; Rapoport BL; Falk S; Daniel F; Jacobs C; Davidson N; Thaler J; Boussard B; Carmichael J
    BMC Cancer; 2004 Jul; 4():36. PubMed ID: 15257756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
    Wulaningsih W; Wardhana A; Watkins J; Yoshuantari N; Repana D; Van Hemelrijck M
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008593. PubMed ID: 26869023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Douillard JY; Cunningham D; Roth AD; Navarro M; James RD; Karasek P; Jandik P; Iveson T; Carmichael J; Alakl M; Gruia G; Awad L; Rougier P
    Lancet; 2000 Mar; 355(9209):1041-7. PubMed ID: 10744089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
    Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
    Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
    Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
    Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
    Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
    Rosati G; Cordio S
    Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
    Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
    Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
    Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.